{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:47:08Z","timestamp":1792072028437,"version":"4.4.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Edaravone dexborneol represents a novel neuroprotective agent utilized in the treatment of acute ischemic stroke (AIS). Preliminary studies indicate that this combination exhibits enhanced therapeutic effects when compared to the use of edaravone alone. The objective of this study was to assess the efficacy and safety of edaravone dexborneol in the management of AIS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement guidelines. A comprehensive search of the PubMed, Cochrane Central, Scopus, and Web of Science databases was performed on December 30, 2024. Subsequently, we screened articles for eligibility, relevant data were extracted, and the risk of bias was assessed utilizing the Cochrane Collaboration Tool 2. The primary outcome evaluated was the efficacy of edaravone dexborneol in the management of AIS, as measured by the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS). Secondary outcomes encompassed improvements in activities of daily living (ADL), reductions in post-stroke depression, inflammation, and hemorrhagic transformation, as well as enhancements in cognitive function, as indicated by Montreal Cognitive Assessment (MoCA) scores. Extracted data from pertinent Randomized Controlled Trials (RCTs) were analyzed using R programming for Windows. All procedures outlined in this study were pre-specified, and the protocol has been registered with PROSPERO under the unique identifier CRD42024626320.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of six randomized controlled trials (RCTs) and one cohort study, all conducted in China and involving 2,942 patients with ischemic stroke (65.6% male), were included. Treatment regimens consisted of intravenous or sublingual edaravone dexborneol administered for 10\u201314\u202fdays. The pooled analysis of functional outcomes at 90\u202fdays, based on five studies, demonstrated a significant benefit, with a 39.5% higher likelihood of achieving favorable mRS scores (OR\u202f=\u202f1.40, 95% CI: 1.18\u20131.65, <jats:italic>p<\/jats:italic> =\u202f0.0001), without evidence of heterogeneity (I<jats:sup>2<\/jats:sup> =\u202f0%). In contrast, pooled analysis of NIHSS outcomes across seven studies using a random-effects model was not significant (SMD\u202f= \u22120.113, 95% CI: \u22120.333 to 0.107, <jats:italic>p<\/jats:italic> =\u202f0.314), with substantial heterogeneity (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u202f72.7%). However, under the common-effect model, a small but statistically significant benefit was observed (SMD\u202f= \u22120.083, 95% CI: \u22120.159 to \u22120.008, <jats:italic>p<\/jats:italic> =\u202f0.030). Sensitivity analyses indicated that several studies (Fu 2024, Hu 2023, Xu 2019, Xu 2024) attenuated the pooled effect, while exclusion of Li 2024 and Hu 2023 reduced heterogeneity to 40.7% but resulted in only borderline significance. Secondary endpoints consistently demonstrated favorable effects, including improved activities of daily living, enhanced cognitive function (MoCA scores), and reduced rates of post-stroke depression, inflammation, and hemorrhagic transformation. Safety analyses revealed that adverse events were generally mild and comparable to controls, with some evidence suggesting a reduction in serious complications such as hemorrhagic transformation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Edaravone dexborneol exhibits considerable potential as a neuroprotective agent in the context of AIS, providing both functional and cognitive advantages, alongside a favorable safety profile. The promising efficacy of this compound underscores the necessity for further comprehensive global studies aimed at optimizing its application and enhancing its relevance across diverse populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier CRD42024626320.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1649476","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:29:35Z","timestamp":1759501775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Khaled","family":"Moghib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Tarek","family":"Hefnawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab M.","family":"Moawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izere","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Uwishema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Meshref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.21037\/atm-2020-cass-15","article-title":"Inflammation of carotid plaques and risk of cerebrovascular events","volume":"8","author":"Poredos","year":"2020","journal-title":"Ann Transl Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1161\/CIRCRESAHA.116.308427","article-title":"Cerebral vascular disease and neurovascular injury in ischemic stroke","volume":"120","author":"Hu","year":"2017","journal-title":"Circ Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomized trials","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/STROKEAHA.122.038466","article-title":"Clinically ineffective reperfusion after endovascular therapy in acute ischemic stroke","volume":"54","author":"Nie","year":"2023","journal-title":"Stroke"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1475021","DOI":"10.3389\/fphar.2024.1475021","article-title":"Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1161\/STROKEAHA.120.031197","article-title":"Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamaneurol.2023.5716","article-title":"Sublingual Edaravone Dexborneol for the treatment of acute ischemic stroke: the TASTE-SL randomized clinical trial","volume":"81","author":"Fu","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1408827","article-title":"Prehospital use of magnesium sulfate as neuroprotection in acute stroke","volume":"372","author":"Saver","year":"2015","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1161\/STROKEAHA.116.012825","article-title":"ALIAS (albumin in acute ischemic stroke) trials: analysis of the combined data from parts 1 and 2","volume":"47","author":"Martin","year":"2016","journal-title":"Stroke"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","article-title":"Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomized controlled trial","volume":"395","author":"Hill","year":"2020","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMoa070240","article-title":"NXY-059 for the treatment of acute ischemic stroke","volume":"357","author":"Shuaib","year":"2007","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S1474-4422(16)00114-9","article-title":"Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation","volume":"15","author":"Chamorro","year":"2016","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"176036","DOI":"10.1016\/j.ejphar.2023.176036","article-title":"Edaravone dexborneol ameliorates cognitive impairment by regulating the NF-\u03baB pathway through AHR and promoting microglial polarization towards the M2 phenotype in mice with bilateral carotid artery stenosis (BCAS)","volume":"957","author":"Li","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/svn-2018-000221","article-title":"Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomized, double-blind, multiple-dose, active-controlled clinical trial","volume":"4","author":"Xu","year":"2019","journal-title":"Stroke Vasc Neurol"},{"key":"ref15","year":"2024"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/svn-2020-000378","article-title":"Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases","volume":"5","author":"Liu","year":"2020","journal-title":"Stroke Vasc Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing the risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range, and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/bmj.331.7521.903","article-title":"Standard deviations and standard errors","volume":"331","author":"Altman","year":"2005","journal-title":"BMJ"},{"key":"ref22","author":"Higgins","year":""},{"key":"ref23","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1037\/\/0033-2909.99.3.400","article-title":"Meta-analytic procedures for combining studies with multiple effect sizes","volume":"99","author":"Rosenthal","year":"1986","journal-title":"Psychol Bull"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-662-47490-7_15","article-title":"Sample size and chi-squared test of fit\u2014a comparison between a random sample approach and a Chi-Square value adjustment method using Swedish adolescent data","volume-title":"Pacific rim objective measurement symposium (PROMS) 2014 conference proceedings","author":"Bergh","year":"2015"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"825383","DOI":"10.1155\/2014\/825383","article-title":"Publication bias in meta-analysis: confidence intervals for Rosenthal\u2019s fail-safe number","volume":"2014","author":"Fragkos","year":"2014","journal-title":"Int Sch Res Notices"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1451060","DOI":"10.3389\/fnins.2024.1451060","article-title":"Observations on the efficacy of edaravone dexborneol in preventing post-stroke depression and its inflammatory mechanism: a prospective, randomized, controlled trial","volume":"18","author":"Xu","year":"2024","journal-title":"Front Neurosci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.36468\/pharmaceutical-sciences.spl.916","article-title":"Therapeutic role of edaravone dexborneol injection in acute ischemic stroke and its influence on nerve function","author":"Li","year":"2024","journal-title":"IJPS"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"20220312","DOI":"10.1515\/tnsci-2022-0312","article-title":"Effects of edaravone dexborneol on neurological function and serum inflammatory factor levels in patients with acute anterior circulation large vessel occlusion stroke","volume":"14","author":"Hu","year":"2023","journal-title":"Transl Neurosci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12883-024-03712-1","article-title":"Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1055\/s-0038-1649503","article-title":"Global burden of stroke","volume":"38","author":"Katan","year":"2018","journal-title":"Semin Neurol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207609","article-title":"Pathophysiology and treatment of stroke: present status and future perspectives","volume":"21","author":"Kuriakose","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"109315","DOI":"10.1016\/j.intimp.2022.109315","article-title":"Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke","volume":"113","author":"Hu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.37349\/ent.2023.00037","article-title":"Neuroprotective agents in acute ischemic stroke","author":"Chia","year":"2023","journal-title":"Explor Neuroprotective Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"47\u201370","DOI":"10.37349\/ent.2023.00037","article-title":"Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis","volume":"3","author":"Wang","year":"2023","journal-title":"Explor Neuroprot Ther"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1649476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:29:36Z","timestamp":1759501776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1649476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":37,"alternative-id":["10.3389\/fneur.2025.1649476"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1649476","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"article-number":"1649476"}}